Data Sheet (Cat.No.T11342L)




G-5555

Chemical Properties

CAS No.: 1648863-90-4
Formula: C25H25CIN6O3

Molecular Weight: 492.96 Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

| Description | G-5555 is a potent inhibitor of p21-activated kinase 1 (PAK1) (Kis: 3.7 nM and 11 nM for PAK1 and PAK2, respectively). | | |
|----------------------------|--|--|--|
| Targets(IC ₅₀) | PAK1: 3.7 nM (ki) PAK2: 11 nM (ki) | | |
| In vitro | G-5555 shows high selectivity for the group I PAKs and it also shows excellent kinase selectivity and inhibits only eight out of the 235 kinases tested other than PAK1 with inhibition >70%: PAK2, PAK3, KHS1, Lck, MST3, MST4, SIK2, and YSK1. The IC50s of G-5555 against SIK2, PAK2, KHS1, MST4, YSK1, MST3, and Lck are 9, 11, 10, 20, 34, 43, 52 nM, respectively. There is a negligible activity for G-5555 against the hERG channel with IC50 more than 10 µM in a patch-clamp assay[1]. G-5555 potently inhibits PAK2 (Ki: 11 nM). G-5555 has obviously greater growth inhibitory activity in cell lines that are PAK-amplified compared to non-amplified lines, in an array of 23 breast cancer cell lines[2]. | | |
| In vivo | G-5555 has low blood clearance and an acceptable half-life. Good oral exposure (AUC = 30 μM•h) and high or bioavailability (F = 80%) are achieved[1]. G-5555 inhibits phosphorylation of the PAK1/2 downstream substrating mitogen-activated protein kinase 1 (MEK1) S298, in an H292 non-small cell lunger cancer (NSCLC) xenograft study in mice. When administered at an oral dose of 25 mg/kg b.i.d., imparts 60% tumor growth inhibition in this model13 and a PAK1 amplified breast cancer xenograft model, MDAMB-175. [2] | | |

Solubility Information

| Solubility | DMSO: 20 mg/mL (40.57 mM) |
|------------|---|
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) |

Page 1 of 2 www.targetmol.com

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|----------|-----------|-----------|
| 1 mM | 2.029 mL | 10.143 mL | 20.286 mL |
| 5 mM | 0.406 mL | 2.029 mL | 4.057 mL |
| 10 mM | 0.203 mL | 1.014 mL | 2.029 mL |
| 50 mM | 0.041 mL | 0.203 mL | 0.406 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- 1. Ndubaku CO, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6.
- 2. Rudolph J, et al. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window. J Med Chem. 2016 Jun 9;59(11):5520-41.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com